Get the app
US › Healthcare

Caribou Biosciences Inc (CRBU)

US · Healthcare · Biotechnology

$0.47+1.12%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$1.5M
Revenue YoY
-43.8%
Net profit
$-24.3M
EPS
$-0.24
EPS estimate
$-0.33
Net margin
-1,619.9%

EPS came in at -0.24 against a street estimate of -0.33 — a beat of 27.3%.

Key statistics

Market cap
$50.4M
Forward P/E
0.0
P/B
1.42
Book value
$0.93
EPS (TTM)
$-1.08
52-week high
$3.54
52-week low
$0.44
50-day MA
$1.37
200-day MA
$1.71
Beta
2.31

Analyst view

Analysts rate Caribou Biosciences Inc a buy (2 buy, 4 hold, 0 sell out of 6) with an average price target of $5.75.

Shareholding

Insiders
8.13%
Institutions
45.15%

Largest institutional holders

FundStake
BlackRock Inc7.29%
Pfizer Inc4.38%
Vanguard Capital Management, LLC3.93%
Mackenzie Investments3.41%
Renaissance Technologies Corp2.59%
Kynam Capital Management, LP2.33%
Geode Capital Management, LLC2.22%
Acadian Asset Management LLC1.66%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Caribou Biosciences Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.